Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT05603910Phase 1Recruiting
- Start
- Apr 2023
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib and pembrolizumab in endometrial carcinoma. Primary endpoints: Recommended Phase 2 Dose of Lenvatinib at 12 weeks, Number of Participants Experiencing Treatment-Related Toxicity: Dose-Limiting Toxicities at 12 weeks and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT05603910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603910.